Market Signals

Doubles share repurchase auth to $150M, $0.40 dividend

Beat FQ1 EPS -$0.28 vs -$0.45 est, $12.1M cash position

$26.5B investment plan to drive 57% EPS growth

FDA CRL for bitopertin, needs Q4 2026 APOLLO data, stock -31%

Board adds $300M to buyback; declares $0.60 dividend

Q4 EPS $2.51 vs $2.74 est, weak 2026 guidance 0.5-1.5% growth

10% workforce cut after Phase 3 failures, stock -9.4%

Unexpected CEO change, stock falls 6%

Q4 EPS $0.72 vs $0.78 est, revenue $393.4M vs $395.7M, stock down 6.3%

Massive EPS beat on one-time items, 2026 guidance flat to 2025, strong Q4 NOI growth 3.3%

Trump to scale back steel/aluminum tariffs, stocks down 2-6%

Q4 adj loss -$0.15 vs $0.06 est, stock down 12%

CPI 2.4% YoY below 2.5% est, rate cut hopes rally

First revenue $3.9M, LYMPHIR launch milestone

First revenue $3.9M beats est, EPS miss, delisting warning

Missed EPS by 20%, revenue 3.4% below estimates

Missed EPS $0.16 vs $0.20 est, Rev beat, 2026 guidance $0.56-$0.60

Missed Q4 rev by 22%, guides up to 10% 2026 growth; FDA flu filing refused

Beat EPS by 72.6%, raised dividend 3% to $0.97, backlog at $39B

Raises quarterly dividend 13% to $0.35 despite Q4 EPS miss